Biotech Blog

Liquid Biopsy for Neurological Diseases: How It Works

March 13, 2026

An in-depth guide to how liquid biopsy is transforming the detection, diagnosis, and monitoring of Alzheimer’s disease, Parkinson’s disease, ALS, and other neurological conditions — without surgery or lumbar puncture.

Introduction: The Diagnostic Challenge of Neurological Disease

Neurological diseases impose an immense and growing burden on global health. Alzheimer’s disease alone affects more than 55 million people worldwide, while Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and traumatic brain injury collectively affect hundreds of millions more. Despite decades of research, diagnosing these conditions — and monitoring their progression — remains extraordinarily difficult.

The fundamental challenge is anatomical: the brain is shielded from the rest of the body by the blood-brain barrier (BBB), a highly selective endothelial membrane that restricts the movement of molecules between the central nervous system (CNS) and peripheral circulation. For most of medical history, meaningful access to CNS disease biology required either invasive cerebrospinal fluid (CSF) sampling via lumbar puncture, costly and scarce neuroimaging such as PET scans, or post-mortem neuropathology.

Liquid biopsy for neurological diseases is changing this paradigm. By detecting and analyzing brain-derived biological material — cell-free DNA, RNA, proteins, and extracellular vesicles — circulating in blood, urine, or CSF, liquid biopsy offers a minimally invasive, scalable, and potentially population-wide approach to CNS disease detection. Companies like NeuroDex are at the forefront of translating this science into clinical tools that can identify neurodegeneration from a standard blood draw, years before symptoms appear.

This article explains how neurological liquid biopsy works, what biomarkers it targets, which diseases it can detect, and how emerging platforms are turning a once-futuristic concept into clinical reality.

1. What Is Liquid Biopsy?

A liquid biopsy is a minimally invasive diagnostic test that detects and analyzes biological material shed by diseased cells into accessible body fluids — most commonly blood, but also urine, saliva, and cerebrospinal fluid. Unlike tissue biopsies, which require surgical sampling and are constrained to a single time point and location, liquid biopsies can be performed repeatedly, capture disease heterogeneity across the whole organ, and reflect real-time disease dynamics.

Liquid biopsy was first developed in oncology, where it has transformed cancer detection and treatment monitoring through analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and tumor-derived extracellular vesicles (EVs). The same principles are now being applied — with important adaptations — to neurological disease, where the stakes for early, non-invasive detection are equally high.

1.1 Key Analytes in Neurological Liquid Biopsy

Four major categories of biomarkers form the foundation of neurological liquid biopsy:

Cell-free DNA (cfDNA) and cell-free RNA (cfRNA): DNA and RNA fragments released from dying or damaged neurons into blood and CSF.
Neurofilament light chain (NfL): A structural neuronal protein released into biofluids upon axonal damage, detectable in both blood and CSF.
Disease-specific proteins: Including amyloid-β, phosphorylated tau (p-tau), α-synuclein, TDP-43, and GFAP — all directly linked to specific neurodegenerative pathologies.
Extracellular vesicles (EVs): Nano-sized, membrane-enclosed particles released by neurons, astrocytes, and microglia that carry a molecular snapshot of their cells of origin into peripheral blood.

Each analyte has distinct biological properties, measurement challenges, and diagnostic utilities. The most powerful neurological liquid biopsy platforms integrate multiple analytes to achieve both high sensitivity and disease-specific accuracy.

2. The Blood-Brain Barrier: The Core Challenge

Understanding neurological liquid biopsy requires understanding why it is technically more demanding than cancer liquid biopsy. In oncology, tumors shed DNA and cells directly into the bloodstream in relatively large quantities. In neurological disease, the blood-brain barrier acts as a formidable gatekeeping structure that dramatically limits the passage of CNS-derived material into peripheral blood.

2.1 How Brain-Derived Material Enters Peripheral Blood

Despite the BBB’s selectivity, several pathways enable CNS-derived biomarkers to reach peripheral circulation in detectable quantities:

Passive diffusion of small molecules and proteins across a partially disrupted BBB — BBB permeability increases in neuroinflammation, TBI, stroke, and neurodegenerative disease.
Active transport mechanisms that carry specific proteins and vesicles across endothelial cells lining the BBB.
Drainage via the glymphatic system — the brain’s waste clearance network — into cervical lymphatics and ultimately into blood.
EV transcytosis: Brain-derived EVs can cross the BBB intact via transcytosis, preserving their molecular cargo and delivering it to peripheral blood where it can be collected and analyzed.

Critically, the quantity of brain-derived material in peripheral blood is orders of magnitude lower than equivalent cancer biomarkers, demanding ultrasensitive detection technologies. This has driven rapid development of single-molecule detection platforms, immunoprecipitation enrichment strategies, and digital assay technologies tailored for low-abundance neurological biomarkers.

3. Neuron-Derived Extracellular Vesicles: The Centrepiece of Neurological Liquid Biopsy

Among all liquid biopsy analytes, neuron-derived extracellular vesicles (NDEs) have emerged as perhaps the most information-rich and disease-specific source of neurological biomarkers. EVs are membrane-enclosed nanoparticles (30–1000 nm) released by virtually all cell types, carrying proteins, nucleic acids, lipids, and metabolites that reflect their cell of origin’s biology.

3.1 Why NDEs Are Uniquely Valuable

Unlike free proteins or nucleic acids that degrade rapidly in blood, EVs encapsulate their cargo within a protective lipid bilayer membrane, dramatically improving biomarker stability. Furthermore, because EVs retain surface proteins from their parent cells — including neural cell adhesion molecule (NCAM), L1CAM, and glutamate receptor subunits — they can be selectively captured from blood using cell-type-specific antibodies, enabling enrichment of brain-derived EVs from the enormous background of non-neural EVs in peripheral blood.

Once isolated, the molecular cargo of NDEs — including intracellular proteins, mRNAs, miRNAs, and lipids — provides a real-time molecular snapshot of neuronal physiology and pathology. Studies have demonstrated that NDE cargo mirrors pathological changes in brain tissue with high fidelity, making them powerful reporters of disease biology that is otherwise inaccessible without surgery.

3.2 NeuroDex and NCAM-Based NDE Enrichment

A leading approach to NDE-based liquid biopsy has been developed by NeuroDex, a company specializing in blood-based neurological diagnostics. NeuroDex’s platform uses immunoaffinity capture with antibodies targeting neural cell adhesion molecule (NCAM) — a protein highly expressed on neurons but absent from most peripheral blood cells — to selectively isolate NDEs from plasma.

This immunocapture approach addresses the fundamental signal-to-noise problem in neurological liquid biopsy: without cell-type-specific enrichment, brain-derived EVs represent only a tiny fraction of the total EV pool in blood, making their specific cargo undetectable against background. NCAM-based enrichment concentrates NDEs to analytically accessible levels, enabling downstream measurement of Alzheimer’s-associated cargo including phosphorylated tau (p-T181), amyloid-β42, and synaptic proteins like synaptotagmin and neurogranin.

NeuroDex’s approach builds on foundational academic work demonstrating the diagnostic potential of L1CAM-enriched NDEs published by Kapogiannis et al. at the National Institute on Aging (NIA) and colleagues, which showed that NDE-associated p-tau and amyloid cargo could predict Alzheimer’s disease progression years before clinical diagnosis.

4. Disease-Specific Biomarkers and What They Reveal

Different neurological diseases leave distinct molecular fingerprints in peripheral biofluids. Here we review the key biomarker signatures for the most prevalent neurological conditions.

4.1 Alzheimer’s Disease

Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β plaques and neurofibrillary tau tangles in the brain, accompanied by progressive neuronal loss. Liquid biopsy biomarkers for AD include:

Amyloid-β42 and the Aβ42/Aβ40 ratio: Reduced plasma Aβ42 and a decreased Aβ42/Aβ40 ratio reflect amyloid plaque sequestration in the brain — a change detectable up to 20 years before symptom onset.
Phosphorylated tau (p-tau181, p-tau217, p-tau231): Elevated plasma p-tau levels — particularly p-tau217 — show remarkable specificity for AD pathology, with accuracy approaching that of CSF and PET imaging in large validation studies.
Neurofilament light chain (NfL): Elevated NfL in blood reflects axonal degeneration across multiple neurodegenerative diseases, serving as a general neurodegeneration marker rather than an AD-specific one.
GFAP (Glial Fibrillary Acidic Protein): Elevated plasma GFAP reflects astrocyte activation and correlates with amyloid burden and disease progression in AD.

A landmark 2020 study published in JAMA demonstrated that plasma p-tau217 distinguished AD from other neurodegenerative diseases with accuracy exceeding 96%, rivaling CSF biomarker performance — a milestone that accelerated clinical adoption of blood-based AD diagnostics.

4.2 Parkinson’s Disease

Parkinson’s disease (PD) is defined pathologically by the aggregation of α-synuclein into Lewy bodies within dopaminergic neurons. Liquid biopsy for PD targets:

α-Synuclein: Both total and oligomeric/aggregated α-synuclein forms in plasma and NDE cargo. NDE-associated α-synuclein appears more disease-specific than free plasma α-synuclein, which is confounded by red blood cell contamination.
DJ-1 (PARK7): A PD-linked protein measurable in plasma and CSF that reflects mitochondrial stress and oxidative damage in dopaminergic neurons.
Phosphorylated α-synuclein (pSer129): The predominant form of α-synuclein in Lewy bodies, with elevated levels in biofluids of PD patients compared to controls.

The Parkinson’s Progression Markers Initiative (PPMI) has been instrumental in validating blood and CSF biomarkers for PD across large, longitudinal cohorts, providing the high-quality dataset infrastructure needed for liquid biopsy biomarker qualification.

4.3 Amyotrophic Lateral Sclerosis (ALS)

ALS is a rapidly progressive motor neuron disease with a critical unmet need for early biomarkers — most patients are diagnosed only after significant motor neuron loss has already occurred. Key liquid biopsy biomarkers in ALS include:

NfL and NfH (neurofilament heavy chain): Dramatically elevated in ALS blood and CSF, correlating with disease progression rate and survival. NfL has been validated as a pharmacodynamic biomarker in ALS clinical trials.
TDP-43: The pathological protein in ~97% of ALS cases, detectable in EVs and plasma in disease-relevant forms.
SOD1 (in familial ALS): Mutant SOD1 protein measurable in CSF as a target engagement biomarker for antisense oligonucleotide (ASO) therapies.

4.4 Multiple Sclerosis

Multiple sclerosis (MS) is characterized by immune-mediated demyelination and neurodegeneration. Liquid biopsy biomarkers for MS include plasma NfL — which rises sharply during relapses and with disease activity — and chitinase-3-like protein 1 (CHI3L1/YKL-40), a marker of astrocyte and microglial activation. NfL is now used in clinical trials as an objective endpoint for neuroprotective MS therapies.

4.5 Traumatic Brain Injury (TBI)

In TBI, brain-derived proteins are released acutely into blood following mechanical damage. The FDA has cleared blood-based TBI diagnostics measuring GFAP and UCH-L1 (ubiquitin C-terminal hydrolase L1) — both proteins released from injured neurons and astrocytes — for use in emergency settings to identify patients unlikely to have intracranial lesions on CT scan, potentially reducing unnecessary radiation exposure.

5. How Neurological Liquid Biopsy Works: The Technical Workflow

Understanding the end-to-end workflow of a neurological liquid biopsy test illuminates both its power and its technical demands.

5.1 Sample Collection and Pre-Analytical Processing

Blood collection for neurological liquid biopsy requires careful attention to pre-analytical variables. Anticoagulant choice (EDTA is preferred over heparin for most EV and protein assays), time from collection to processing, freeze-thaw cycles, and centrifugation speed all critically affect biomarker recovery and integrity. Standardized collection protocols — ideally aligned with ISEV and NIA-AA guidance — are essential for reproducible results.

5.2 Biomarker Enrichment and Isolation

For EV-based approaches, plasma is subjected to sequential centrifugation or size exclusion chromatography to separate EVs from larger particles and soluble proteins. For NDE-specific analysis, immunoaffinity capture using anti-NCAM, anti-L1CAM, or other neural surface marker antibodies is applied to selectively enrich brain-derived EVs from the total EV pool — a critical step for achieving CNS-specific signal.

5.3 Biomarker Detection and Quantification

Ultra-sensitive detection platforms are required to measure the extremely low concentrations of neurological biomarkers in blood. Key technologies include:

Single-molecule array (Simoa): The Quanterix Simoa platform can detect proteins at femtomolar concentrations — 1,000-fold more sensitive than conventional ELISA — and is the gold-standard platform for plasma NfL, GFAP, and p-tau measurement.
Digital ELISA: Compartmentalizes single immune complexes into nanowells to enable digital counting of individual molecules.
Mass spectrometry: LC-MS/MS-based quantification of tau peptides and amyloid-β isoforms offers high specificity and multiplex capability.
Proximity extension assay (PEA): Olink Proteomics’ PEA technology enables multiplexed quantification of hundreds of proteins from small plasma volumes with high sensitivity and specificity.

5.4 Data Analysis and Clinical Interpretation

Raw biomarker concentrations are normalized, quality-controlled, and interpreted in the context of patient age, sex, APOE genotype (for AD biomarkers), and clinical presentation. Machine learning algorithms trained on large cohort data are increasingly used to generate composite risk scores that integrate multiple biomarkers into a single diagnostic output — improving accuracy over any individual marker.

6. Clinical Applications: Where Neurological Liquid Biopsy Is Making an Impact

6.1 Preclinical Disease Detection and Risk Stratification

Perhaps the greatest promise of neurological liquid biopsy lies in detecting disease biology years or even decades before clinical symptoms emerge. In Alzheimer’s disease, plasma amyloid-β and p-tau changes are detectable 15–20 years before dementia onset, creating a window for preventive intervention that does not exist with symptom-based diagnosis. Population-scale screening using blood-based AD biomarkers could identify individuals for enrollment in prevention trials or early treatment — a paradigm shift analogous to cholesterol screening for cardiovascular disease.

6.2 Differential Diagnosis

Many neurological diseases share overlapping clinical symptoms. Distinguishing Alzheimer’s disease from frontotemporal dementia, Parkinson’s disease from atypical parkinsonian syndromes, or ALS from other motor neuron diseases is clinically challenging but therapeutically critical. Liquid biopsy biomarker profiles — particularly multi-analyte panels — can aid differential diagnosis by providing disease-specific molecular evidence to complement clinical assessment.

6.3 Disease Progression Monitoring

Longitudinal liquid biopsy allows tracking of disease progression and neurodegeneration over time. Rising plasma NfL trajectories signal accelerating neuronal loss in ALS, MS relapse, and AD progression. Serial biomarker monitoring can identify disease acceleration, inform prognosis, and guide clinical management decisions including escalation of care or enrollment in interventional trials.

6.4 Therapeutic Response Monitoring

Liquid biopsy has become an essential tool in CNS drug development. Plasma NfL has been qualified as a pharmacodynamic biomarker in ALS, SMA (spinal muscular atrophy), and MS clinical trials, enabling objective assessment of whether a therapy is reducing neurodegeneration — even before functional improvements become measurable. Plasma p-tau217 reductions have been used to confirm target engagement in anti-amyloid AD trials, and plasma Aβ42/40 ratio changes track amyloid plaque clearance in response to anti-amyloid immunotherapy.

6.5 Post-Approval Drug Monitoring

As disease-modifying therapies for neurological diseases reach clinical approval — including anti-amyloid antibodies for AD such as lecanemab and donanemab — liquid biopsy will play a growing role in monitoring treatment response, detecting side effects such as amyloid-related imaging abnormalities (ARIA), and selecting patients most likely to benefit from treatment.

7. Comparative Landscape: Blood vs. CSF vs. Imaging

Understanding liquid biopsy’s clinical positioning requires comparison with established diagnostic modalities.

7.1 Cerebrospinal Fluid

CSF, obtained by lumbar puncture, has long been the gold standard for neurological biomarker measurement given its direct proximity to the CNS. CSF amyloid-β and p-tau assays have been used in research and specialized clinics for over two decades. However, lumbar puncture is invasive, associated with headache and patient discomfort, and requires trained specialists — making it unsuitable for population-scale screening or frequent longitudinal monitoring. Blood-based liquid biopsy tests, while slightly less sensitive for some analytes, offer a dramatically more accessible and scalable alternative.

7.2 PET Imaging

Amyloid and tau PET imaging provide exquisitely detailed, spatially resolved maps of pathological protein accumulation in the brain. They remain the most accurate tools for confirming AD pathology in research and specialized clinical settings. However, PET scans cost several thousand dollars per scan, expose patients to radioactive tracers, require specialized scanners available only at major academic centers, and cannot be performed frequently. Blood-based biomarkers are not expected to replace PET in all contexts, but rather to serve as accessible first-line screening tools that select patients for confirmatory PET or CSF testing.

7.3 Blood-Based Liquid Biopsy

Blood tests offer unparalleled accessibility, scalability, and repeatability. They can be performed at any clinical laboratory, are well-tolerated, can be repeated as frequently as monthly, and cost a fraction of PET imaging. The 2020–2024 period saw blood-based p-tau217 assays validated against PET and CSF standards in large, diverse cohorts, with accuracy sufficient for clinical use. Several blood-based AD diagnostic tests have received FDA Breakthrough Device designation, signaling their potential transformative clinical impact.

8. Leading Platforms and Technologies in Neurological Liquid Biopsy

8.1 NeuroDex — Neuron-Derived Exosome Profiling

NeuroDex has developed a proprietary platform for isolating and profiling neuron-derived exosomes (NDEs) from peripheral blood using NCAM-based immunoaffinity capture. By enriching for brain-specific EVs, NeuroDex’s assay enables quantification of Alzheimer’s pathology markers — including p-tau and amyloid-β — from a standard blood draw, with the selectivity advantages of CNS-specific EV isolation. The platform’s ability to access intracellular neuronal proteins via the EV cargo compartment opens diagnostic windows not achievable with free-protein plasma assays alone.

8.2 Quanterix — Ultra-Sensitive Protein Detection

Quanterix‘s Simoa (Single Molecule Array) technology is the leading platform for ultra-sensitive protein biomarker quantification in neurological liquid biopsy. Simoa underpins the majority of published clinical studies on plasma NfL, GFAP, p-tau, and amyloid-β, and several Simoa-based assays have received CE marking in Europe and are in FDA review pathways in the United States.

8.3 Fujirebio and Roche — Clinical-Grade AD Diagnostics

Both Fujirebio and Roche Diagnostics have developed fully automated, laboratory-scale blood-based Alzheimer’s biomarker assays measuring p-tau217, p-tau181, Aβ42/40, and GFAP. These assays are integrated into high-throughput clinical analyzers, enabling adoption in hospital laboratory networks without specialized research infrastructure — a critical step toward clinical mainstream adoption.

8.4 C2N Diagnostics — Preclinical AD Screening

C2N Diagnostics developed PrecivityAD2, a mass spectrometry-based blood test measuring the Aβ42/40 ratio and p-tau217 for assessment of brain amyloid status. It has received FDA Breakthrough Device designation and represents one of the most analytically validated blood-based AD tests currently available, with clinical accuracy data published in top-tier journals.

9. Challenges and Limitations

9.1 Signal Dilution and Detection Sensitivity

Brain-derived biomarkers in peripheral blood are present at extremely low concentrations — often in the femtomolar to attomolar range. Even ultrasensitive platforms like Simoa operate near their analytical limits for some analytes, and further improvements in detection sensitivity are needed to reliably measure biomarkers in early pre-symptomatic disease stages where concentrations are lowest.

9.2 Specificity: Brain vs. Peripheral Sources

Many putative neurological biomarkers are not brain-exclusive. NfL, for example, is released by peripheral neurons as well as CNS neurons, confounding interpretation in patients with peripheral neuropathy. GFAP is expressed in peripheral glia. Strategies for achieving true CNS specificity — such as NDE immunoenrichment — are active areas of development and will be critical for clinical utility in patients with comorbid conditions.

9.3 Standardization and Reference Materials

Different platforms, antibodies, and calibrators yield divergent absolute concentration values for the same biomarker, complicating cross-study comparisons and multi-site clinical trials. Development of certified reference materials and harmonized assay standards — a process underway through partnerships between the NIA, NIST, and clinical diagnostics industry — is essential for widespread clinical implementation.

9.4 Diverse Population Validation

Most large-scale neurological liquid biopsy validation studies have been conducted predominantly in White, European-ancestry cohorts. Biomarker performance may differ across genetic backgrounds, APOE genotype, comorbidities, and socioeconomic contexts. Deliberate inclusion of diverse populations in validation studies is both a scientific necessity and an equity imperative.

10. The Road Ahead: Future Directions

The next five years are likely to deliver transformative advances in neurological liquid biopsy. Several key developments are anticipated:

FDA clearance and clinical adoption of blood-based AD diagnostics: Multiple blood tests for Alzheimer’s disease are expected to receive FDA clearance for clinical use, enabling their integration into primary care and neurology practice for the first time.
Multi-disease liquid biopsy panels: Single blood tests measuring panels of neurological biomarkers capable of simultaneously flagging Alzheimer’s, Parkinson’s, ALS, and MS will emerge, enabling broad neurological screening from a single draw.
Longitudinal digital health integration: Wearable devices, digital cognitive assessments, and repeated liquid biopsy measurements will be integrated into comprehensive neurological health monitoring platforms, enabling continuous surveillance of brain health over a lifetime.
EV multi-omics panels: NDE-based platforms profiling protein, RNA, and lipid cargo simultaneously — enabled by single-EV multi-omics technologies — will achieve unprecedented diagnostic depth and disease specificity.
AI-powered diagnostic algorithms: Machine learning models trained on multi-modal data — liquid biopsy biomarkers, genetics, imaging, cognitive testing — will provide individualized risk scores for neurological disease onset and progression, enabling truly personalized neurological medicine. Tools being developed by companies like NeuroDex exemplify this convergent approach.

Conclusion

Liquid biopsy for neurological diseases represents one of the most consequential advances in modern neurology. By detecting brain-derived biological material in peripheral blood — circumventing the blood-brain barrier through biomarker-specific enrichment strategies, EV-based capture, and ultra-sensitive detection — it is creating a new diagnostic paradigm for conditions that have historically been detected far too late to intervene meaningfully.

From neuron-derived exosome profiling platforms like NeuroDex to ultrasensitive protein assays from Quanterix and automated clinical analyzers from Roche and Fujirebio, the technological ecosystem for neurological liquid biopsy is maturing rapidly. The coming decade promises to deliver clinically validated, accessible blood tests for Alzheimer’s disease, Parkinson’s disease, ALS, and beyond — transforming neurological care from a reactive, symptom-driven specialty into one that can identify and treat disease at its earliest, most treatable stages.